EHA 2023 | Phase II study of acalabrutinib, lenalidomide & rituximab for high tumor burden follicular lymphoma
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an update on a Phase II trial (NCT04404088) evaluating the combination of acalabrutinib, lenalidomide, and rituximab for patients with high tumor burden previously untreated follicular lymphoma (FL). Dr Strati discusses the study’s rationale and the future expansion of the trial based on the encouraging safety and efficacy data observed after just six treatment cycles. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
PS is a consultant for Roche-Genentech, Kite/Gilead, Hutchison MediPharma, AstraZeneca-Acerta, ADC Therapeutics, Sobi, and TG Therapeutics; he has received research funds from AstraZeneca-Acerta, ALX Oncology, and ADC Therapeutics.
